BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19540208)

  • 1. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
    Bodart V; Anastassov V; Darkes MC; Idzan SR; Labrecque J; Lau G; Mosi RM; Neff KS; Nelson KL; Ruzek MC; Patel K; Santucci Z; Scarborough R; Wong RS; Bridger GJ; Macfarland RT; Fricker SP
    Biochem Pharmacol; 2009 Oct; 78(8):993-1000. PubMed ID: 19540208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
    Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
    Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
    Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
    Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.
    Fricker SP; Anastassov V; Cox J; Darkes MC; Grujic O; Idzan SR; Labrecque J; Lau G; Mosi RM; Nelson KL; Qin L; Santucci Z; Wong RS
    Biochem Pharmacol; 2006 Aug; 72(5):588-96. PubMed ID: 16815309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
    J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bryostatin-5 blocks stromal cell-derived factor-1 induced chemotaxis via desensitization and down-regulation of cell surface CXCR4 receptors.
    He X; Fang L; Wang J; Yi Y; Zhang S; Xie X
    Cancer Res; 2008 Nov; 68(21):8678-86. PubMed ID: 18974109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and recurrent neutrophil mobilization regulated by T134, a CXCR4 peptide antagonist.
    Iyer CV; Evans RJ; Lou Q; Lin D; Wang J; Kohn W; Yan LZ; Pulley S; Peng SB
    Exp Hematol; 2008 Sep; 36(9):1098-109. PubMed ID: 18495324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
    Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
    Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cloning, mRNA distribution, and functional expression of an avian counterpart of the chemokine receptor/HIV coreceptor CXCR4.
    Liang TS; Hartt JK; Lu S; Martins-Green M; Gao JL; Murphy PM
    J Leukoc Biol; 2001 Feb; 69(2):297-305. PubMed ID: 11272281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S1P(1) overexpression stimulates S1P-dependent chemotaxis of human CD34+ hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent migration and in vivo homing.
    Ryser MF; Ugarte F; Lehmann R; Bornhäuser M; Brenner S
    Mol Immunol; 2008 Nov; 46(1):166-71. PubMed ID: 18760838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003.
    Abraham M; Biyder K; Begin M; Wald H; Weiss ID; Galun E; Nagler A; Peled A
    Stem Cells; 2007 Sep; 25(9):2158-66. PubMed ID: 17525235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model.
    Kitaori T; Ito H; Schwarz EM; Tsutsumi R; Yoshitomi H; Oishi S; Nakano M; Fujii N; Nagasawa T; Nakamura T
    Arthritis Rheum; 2009 Mar; 60(3):813-23. PubMed ID: 19248097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5.
    Andrews G; Jones C; Wreggett KA
    Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
    Rosenkilde MM; Gerlach LO; Hatse S; Skerlj RT; Schols D; Bridger GJ; Schwartz TW
    J Biol Chem; 2007 Sep; 282(37):27354-27365. PubMed ID: 17599916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.
    Bridger GJ; Skerlj RT; Hernandez-Abad PE; Bogucki DE; Wang Z; Zhou Y; Nan S; Boehringer EM; Wilson T; Crawford J; Metz M; Hatse S; Princen K; De Clercq E; Schols D
    J Med Chem; 2010 Feb; 53(3):1250-60. PubMed ID: 20043638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess.
    Chu PY; Zatta A; Kiriazis H; Chin-Dusting J; Du XJ; Marshall T; Kaye DM
    Circ Heart Fail; 2011 Sep; 4(5):651-8. PubMed ID: 21685249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis.
    Zernecke A; Bot I; Djalali-Talab Y; Shagdarsuren E; Bidzhekov K; Meiler S; Krohn R; Schober A; Sperandio M; Soehnlein O; Bornemann J; Tacke F; Biessen EA; Weber C
    Circ Res; 2008 Feb; 102(2):209-17. PubMed ID: 17991882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.
    Hatse S; Princen K; Bridger G; De Clercq E; Schols D
    FEBS Lett; 2002 Sep; 527(1-3):255-62. PubMed ID: 12220670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.
    Thoma G; Streiff MB; Kovarik J; Glickman F; Wagner T; Beerli C; Zerwes HG
    J Med Chem; 2008 Dec; 51(24):7915-20. PubMed ID: 19053768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo.
    Yang L; Jackson E; Woerner BM; Perry A; Piwnica-Worms D; Rubin JB
    Cancer Res; 2007 Jan; 67(2):651-8. PubMed ID: 17234775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.